非小細胞肺癌ＭＶＰ療法におけるＧ‐ＣＳＦ投与時期の検討

DOI Web Site 参考文献19件

書誌事項

タイトル別名
  • A Prospective Clinical Trial on the Optimum Time for Initiation of G-CSF Therapy in the Treatment of Non-small Cell Lung Cancer with the MVP Regimen.

この論文をさがす

抄録

We investigated the optimum time for initiation of G-CSF therapy in the treatment of non-small cell lung cancer with the MVP regimen.The subjects consisted of 28 patients with a post-MVP neutrophil count less than 1, 000/mm3.With the first course of MVP, G-CSF was started after the neutrophil count decreased to less than 1, 000/mm3 (arm A).With the second course of MVP, preventive G-CSF treatment was given from day 6 (arm B).Arm B showed a shorter duration of the nadir neutrophil count and the period with a count less than 1, 000/mm3, but there was no significant difference between the two arms.However, a neutrophil count of 2, 000/mm3 or more was reached significantly faster in arm B, with this count only being attained after 17 days in arm A.Post-MVP febrile neutropenia developed in 4 arm A patients and 5 arm B patients.The GCSF dose in arm A was half of that for arm B, with the difference being significant. Considering the lack of a significant preventive effect on the development of neutropenia in arm B, despite the higher G-CSF dose and the similar anti-infection effect of arm A, we concluded that arm A seemed to be a superior regimen.

収録刊行物

  • 肺癌

    肺癌 35 (7), 901-909, 1995

    特定非営利活動法人 日本肺癌学会

参考文献 (19)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ